Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 146 entries
Sorted by: Best Match Show Resources per page
HPV Carcinomas in Immunocompromised Patients.

Journal of clinical medicine

Reusser NM, Downing C, Guidry J, Tyring SK.
PMID: 26239127
J Clin Med. 2015 Jan 29;4(2):260-81. doi: 10.3390/jcm4020260.

Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide and can result in pre-malignancies or overt malignancies of the skin and mucosal surfaces. HPV-related illnesses are an important personal and public health problem causing physical, mental,...

Cite
Reusser NM, Downing C, Guidry J, et al. HPV Carcinomas in Immunocompromised Patients. J Clin Med. 2015;4(2):260-81doi: 10.3390/jcm4020260.
Reusser, N. M., Downing, C., Guidry, J., & Tyring, S. K. (2015). HPV Carcinomas in Immunocompromised Patients. Journal of clinical medicine, 4(2), 260-81. https://doi.org/10.3390/jcm4020260
Reusser, Nicole M, et al. "HPV Carcinomas in Immunocompromised Patients." Journal of clinical medicine vol. 4,2 (2015): 260-81. doi: https://doi.org/10.3390/jcm4020260
Reusser NM, Downing C, Guidry J, Tyring SK. HPV Carcinomas in Immunocompromised Patients. J Clin Med. 2015 Jan 29;4(2):260-81. doi: 10.3390/jcm4020260. PMID: 26239127; PMCID: PMC4470124.
Copy Download .nbib Format: NLM
Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV.

Journal of clinical medicine

Kollipara R, Ekhlassi E, Downing C, Guidry J, Lee M, Tyring SK.
PMID: 26239450
J Clin Med. 2015 Apr 24;4(5):832-46. doi: 10.3390/jcm4050832.

Human papillomavirus (HPV) is the most common sexually transmitted disease. Via infection of the basal epithelial cells, HPV causes numerous malignancies and noncancerous cutaneous manifestations. Noncancerous cutaneous manifestations of HPV, including common, plantar, plane, and anogenital warts, are among...

Cite
Kollipara R, Ekhlassi E, Downing C, et al. Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV. J Clin Med. 2015;4(5):832-46doi: 10.3390/jcm4050832.
Kollipara, R., Ekhlassi, E., Downing, C., Guidry, J., Lee, M., & Tyring, S. K. (2015). Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV. Journal of clinical medicine, 4(5), 832-46. https://doi.org/10.3390/jcm4050832
Kollipara, Ramya, et al. "Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV." Journal of clinical medicine vol. 4,5 (2015): 832-46. doi: https://doi.org/10.3390/jcm4050832
Kollipara R, Ekhlassi E, Downing C, Guidry J, Lee M, Tyring SK. Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV. J Clin Med. 2015 Apr 24;4(5):832-46. doi: 10.3390/jcm4050832. PMID: 26239450; PMCID: PMC4470201.
Copy Download .nbib Format: NLM
Cerebral microsporidiosis manifesting as progressive multifocal leukoencephalopathy in an HIV-infected individual - a case report.

AIDS research and therapy

Loignon M, Labrecque LG, Bard C, Robitaille Y, Toma E.
PMID: 25057277
AIDS Res Ther. 2014 Jul 15;11:20. doi: 10.1186/1742-6405-11-20. eCollection 2014.

Microsporidia have become increasingly recognized as opportunistic pathogens since the genesis of the AIDS epidemic. The incidence of microsporidiosis has decreased with the advent of combination antiretroviral therapy but it is frequently reported in non-HIV immunosuppressed patients and as...

Cite
Loignon M, Labrecque LG, Bard C, et al. Cerebral microsporidiosis manifesting as progressive multifocal leukoencephalopathy in an HIV-infected individual - a case report. AIDS Res Ther. 2014;11:20doi: 10.1186/1742-6405-11-20.
Loignon, M., Labrecque, L. G., Bard, C., Robitaille, Y., & Toma, E. (2014). Cerebral microsporidiosis manifesting as progressive multifocal leukoencephalopathy in an HIV-infected individual - a case report. AIDS research and therapy, 1120. https://doi.org/10.1186/1742-6405-11-20
Loignon, Maude, et al. "Cerebral microsporidiosis manifesting as progressive multifocal leukoencephalopathy in an HIV-infected individual - a case report." AIDS research and therapy vol. 11 (2014): 20. doi: https://doi.org/10.1186/1742-6405-11-20
Loignon M, Labrecque LG, Bard C, Robitaille Y, Toma E. Cerebral microsporidiosis manifesting as progressive multifocal leukoencephalopathy in an HIV-infected individual - a case report. AIDS Res Ther. 2014 Jul 15;11:20. doi: 10.1186/1742-6405-11-20. eCollection 2014. PMID: 25057277; PMCID: PMC4107492.
Copy Download .nbib Format: NLM
Cytomegalovirus Treatment.

Current treatment options in infectious diseases

Tan BH.
PMID: 25999800
Curr Treat Options Infect Dis. 2014;6(3):256-270. doi: 10.1007/s40506-014-0021-5.

In treating cytomegalovirus (CMV) infection, it is crucial to decide whether one is treating pre-emptively or if one is treating established disease. Disease may be further divided into viral syndrome and tissue-invasive disease. Generally, mild disease in immunosuppressed patients...

Cite
Tan BH. Cytomegalovirus Treatment. Curr Treat Options Infect Dis. 2014;6(3):256-270doi: 10.1007/s40506-014-0021-5.
Tan, B. H. (2014). Cytomegalovirus Treatment. Current treatment options in infectious diseases, 6(3), 256-270. https://doi.org/10.1007/s40506-014-0021-5
Tan, Ban Hock. "Cytomegalovirus Treatment." Current treatment options in infectious diseases vol. 6,3 (2014): 256-270. doi: https://doi.org/10.1007/s40506-014-0021-5
Tan BH. Cytomegalovirus Treatment. Curr Treat Options Infect Dis. 2014;6(3):256-270. doi: 10.1007/s40506-014-0021-5. PMID: 25999800; PMCID: PMC4431713.
Copy Download .nbib Format: NLM
Progressive multifocal leukoencephalopathy.

Current treatment options in neurology

Aksamit AJ.
PMID: 18579021
Curr Treat Options Neurol. 2008 May;10(3):178-85. doi: 10.1007/s11940-008-0019-8.

Treatment of progressive multifocal leukoencephalopathy (PML) in a patient with exogenous immunosuppression starts with discontinuation of immunosuppressive medication. The restored host immunity will clear JC virus, the cause of PML, from the brain via cell-mediated immune mechanisms. Patients with...

Cite
Aksamit AJ. Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol. 2008;10(3):178-85doi: 10.1007/s11940-008-0019-8.
Aksamit, A. J. (2008). Progressive multifocal leukoencephalopathy. Current treatment options in neurology, 10(3), 178-85. https://doi.org/10.1007/s11940-008-0019-8
Aksamit, Allen J. "Progressive multifocal leukoencephalopathy." Current treatment options in neurology vol. 10,3 (2008): 178-85. doi: https://doi.org/10.1007/s11940-008-0019-8
Aksamit AJ. Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol. 2008 May;10(3):178-85. doi: 10.1007/s11940-008-0019-8. PMID: 18579021.
Copy Download .nbib Format: NLM
Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient.

Case reports in neurology

Park JH, Ryoo S, Noh HJ, Seo JM, Kang HH, Shin JS, Seo SW, Na DL.
PMID: 22114583
Case Rep Neurol. 2011 Sep;3(3):258-62. doi: 10.1159/000333780. Epub 2011 Oct 14.

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a demyelinating central nervous system disease caused by JC virus (JCV) reactivation in immunocompromised patients. The disease course of PML is often progressive, fatal and at present, there are few reports on successful...

Cite
Park JH, Ryoo S, Noh HJ, et al. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep Neurol. 2011;3(3):258-62doi: 10.1159/000333780.
Park, J. H., Ryoo, S., Noh, H. J., Seo, J. M., Kang, H. H., Shin, J. S., Seo, S. W., & Na, D. L. (2011). Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case reports in neurology, 3(3), 258-62. https://doi.org/10.1159/000333780
Park, Jae Hyun, et al. "Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient." Case reports in neurology vol. 3,3 (2011): 258-62. doi: https://doi.org/10.1159/000333780
Park JH, Ryoo S, Noh HJ, Seo JM, Kang HH, Shin JS, Seo SW, Na DL. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep Neurol. 2011 Sep;3(3):258-62. doi: 10.1159/000333780. Epub 2011 Oct 14. PMID: 22114583; PMCID: PMC3220895.
Copy Download .nbib Format: NLM
Topical cidofovir for treatment of resistant viral infections.

International journal of pharmaceutical compounding

McElhiney LF.
PMID: 23974309
Int J Pharm Compd. 2006 Sep-Oct;10(5):324-8.

Cidofovir is a broad-spectrum antiviral agent with activity against several DNA viruses. An application to approve the use of topical cidofovir for acyclovir-resistant herpes virus infection was denied by the US Food and Drug Administration owing to the lack...

Cite
McElhiney LF. Topical cidofovir for treatment of resistant viral infections. Int J Pharm Compd. 2006;10(5):324-8
McElhiney, L. F. (2006). Topical cidofovir for treatment of resistant viral infections. International journal of pharmaceutical compounding, 10(5), 324-8.
McElhiney, Linda F. "Topical cidofovir for treatment of resistant viral infections." International journal of pharmaceutical compounding vol. 10,5 (2006): 324-8.
McElhiney LF. Topical cidofovir for treatment of resistant viral infections. Int J Pharm Compd. 2006 Sep-Oct;10(5):324-8. PMID: 23974309.
Copy Download .nbib Format: NLM
Effect of combinations of antiviral drugs on herpes simplex encephalitis.

Drug design, development and therapy

Gebhardt BM, Focher F, Eberle R, Manikowski A, Wright GE.
PMID: 20054446
Drug Des Devel Ther. 2009 Dec 29;3:289-94. doi: 10.2147/dddt.s8133.

2-Phenylamino-6-oxo-9-(4-hydroxybutyl)purine (HBPG) is a thymidine kinase inhibitor that prevents encephalitic death in mice caused by herpes simplex virus (HSV) types 1 and 2, although its potency is somewhat less than that of acyclovir (ACV). The present study was undertaken...

Cite
Gebhardt BM, Focher F, Eberle R, et al. Effect of combinations of antiviral drugs on herpes simplex encephalitis. Drug Des Devel Ther. 2009;3:289-94doi: 10.2147/dddt.s8133.
Gebhardt, B. M., Focher, F., Eberle, R., Manikowski, A., & Wright, G. E. (2009). Effect of combinations of antiviral drugs on herpes simplex encephalitis. Drug design, development and therapy, 3289-94. https://doi.org/10.2147/dddt.s8133
Gebhardt, Bryan M, et al. "Effect of combinations of antiviral drugs on herpes simplex encephalitis." Drug design, development and therapy vol. 3 (2009): 289-94. doi: https://doi.org/10.2147/dddt.s8133
Gebhardt BM, Focher F, Eberle R, Manikowski A, Wright GE. Effect of combinations of antiviral drugs on herpes simplex encephalitis. Drug Des Devel Ther. 2009 Dec 29;3:289-94. doi: 10.2147/dddt.s8133. PMID: 20054446; PMCID: PMC2802127.
Copy Download .nbib Format: NLM
Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Future virology

Smee DF.
PMID: 24563659
Future Virol. 2013 Sep;8(9):891-901. doi: 10.2217/fvl.13.76.

Antiviral agents are being sought as countermeasures for the potential deliberate release of smallpox (variola) and monkeypox viruses, for the treatment of naturally acquired monkeypox virus infections, and as therapy for complications due to smallpox (live-attenuated vaccinia virus) vaccination...

Cite
Smee DF. Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012. Future Virol. 2013;8(9):891-901doi: 10.2217/fvl.13.76.
Smee, D. F. (2013). Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012. Future virology, 8(9), 891-901. https://doi.org/10.2217/fvl.13.76
Smee, Donald F. "Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012." Future virology vol. 8,9 (2013): 891-901. doi: https://doi.org/10.2217/fvl.13.76
Smee DF. Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012. Future Virol. 2013 Sep;8(9):891-901. doi: 10.2217/fvl.13.76. PMID: 24563659; PMCID: PMC3929309.
Copy Download .nbib Format: NLM
[No title available]

La Revue du praticien

Agut H, Burrel S, Bonnafous P, Boutolleau D.
PMID: 30512372
Rev Prat. 2016 Nov;66(9):1007-1014.

Research for novel antivirals: where are we going? Antiviral drugs have become a critical component of anti-infective treatments, as illustrated by the development of antiretrovirals and antiviral drugs directed against hepatitis B and C viruses. Several other molecules are...

Cite
Agut H, Burrel S, Bonnafous P, et al. Où en est la recherche sur les antiviraux ? . Rev Prat. 2016;66(9):1007-1014
Agut, H., Burrel, S., Bonnafous, P., & Boutolleau, D. (2016). Où en est la recherche sur les antiviraux ? . La Revue du praticien, 66(9), 1007-1014.
Agut, Henri, et al. "Où en est la recherche sur les antiviraux ?" . La Revue du praticien vol. 66,9 (2016): 1007-1014.
Agut H, Burrel S, Bonnafous P, Boutolleau D. Où en est la recherche sur les antiviraux ? . Rev Prat. 2016 Nov;66(9):1007-1014. French. PMID: 30512372.
Copy Download .nbib Format: NLM
Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review.

Infection and drug resistance

El Helou G, Razonable RR.
PMID: 31239725
Infect Drug Resist. 2019 Jun 04;12:1481-1491. doi: 10.2147/IDR.S180908. eCollection 2019.

Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the...

Cite
El Helou G, Razonable RR. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist. 2019;12:1481-1491doi: 10.2147/IDR.S180908.
El Helou, G., & Razonable, R. R. (2019). Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infection and drug resistance, 121481-1491. https://doi.org/10.2147/IDR.S180908
El Helou, Guy, and Razonable, Raymund R. "Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review." Infection and drug resistance vol. 12 (2019): 1481-1491. doi: https://doi.org/10.2147/IDR.S180908
El Helou G, Razonable RR. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist. 2019 Jun 04;12:1481-1491. doi: 10.2147/IDR.S180908. eCollection 2019. PMID: 31239725; PMCID: PMC6556539.
Copy Download .nbib Format: NLM
Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation.

Case reports in infectious diseases

Van Genechten T, van Heerden J, Bauters T, Dhooge C.
PMID: 31970003
Case Rep Infect Dis. 2020 Jan 07;2020:5981289. doi: 10.1155/2020/5981289. eCollection 2020.

Immunocompromised patients, including hematopoietic stem cell transplantation (HSCT), HIV, and malnourished patients, are at increased risk for viral infections with high incidences of morbidity and mortality. In HSCT patients, the infection risk is increased until immune reconstitution is re-established....

Cite
Van Genechten T, van Heerden J, Bauters T, et al. Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation. Case Rep Infect Dis. 2020;2020:5981289doi: 10.1155/2020/5981289.
Van Genechten, T., van Heerden, J., Bauters, T., & Dhooge, C. (2020). Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation. Case reports in infectious diseases, 20205981289. https://doi.org/10.1155/2020/5981289
Van Genechten, T, et al. "Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation." Case reports in infectious diseases vol. 2020 (2020): 5981289. doi: https://doi.org/10.1155/2020/5981289
Van Genechten T, van Heerden J, Bauters T, Dhooge C. Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation. Case Rep Infect Dis. 2020 Jan 07;2020:5981289. doi: 10.1155/2020/5981289. eCollection 2020. PMID: 31970003; PMCID: PMC6973187.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 146 entries